In China, ovarian cancer patients' sensitivity to platinum-based chemotherapy is predicted by HRD detection.

Published Date: 26 Apr 2023

A biomarker known as homologous recombination deficiency (HRD) indicates whether breast cancer will be treated with platinum-based chemotherapy in the first instance or with PARP inhibitors for the treatment of ovarian cancer. However, there is little documented research.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

2.

More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer

3.

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

4.

Mapping lifelong chronic health risks for childhood cancer survivors

5.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot